Keyword: Luye Pharma Group
Eisai starts pivotal BAN2401 Alzheimer's trial; AZ helps build new life sciences hub in China; Ono secures a chance to license British I-O programs.
Takeda plans major cuts after $62 billion Shire buyout; Ascletis files for HK IPO under new listing rules; AZ hands Seroquel rights to Luye Pharma.
AstraZeneca is back at it again with its asset sales. The company offloaded certain Seroquel rights to Luye Pharma for up to $538 million.